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Chronic suppurative lung disease (CSLD) and bronchiectasis in children and adolescents 
are important causes of respiratory morbidity and reduced quality of life (QoL), also lead-
ing to subsequent premature death during adulthood. Acute respiratory exacerbations 
in pediatric CSLD and bronchiectasis are important markers of disease control clinically, 
given that they impact upon QoL and increase health-care-associated costs and can 
adversely affect future lung functioning. Preventing exacerbations in this population is, 
therefore, likely to have significant individual, familial, societal, and health-sector ben-
efits. In this review, we focus on therapeutic interventions, such as drugs (antibiotics, 
mucolytics, hyperosmolar agents, bronchodilators, corticosteroids, non-steroidal anti-in-
flammatory agents), vaccines and physiotherapy, and care-planning, such as post-hos-
pitalization management and health promotion strategies, including exercise, diet, and 
reducing exposure to environmental toxicants. The review identified a conspicuous lack 
of moderate or high-quality evidence for preventing respiratory exacerbations in children 
and adolescents with CSLD or bronchiectasis. Given the short- and long-term impact 
of exacerbations upon individuals, their families, and society as a whole, large studies 
addressing interventions at the primary and tertiary prevention phases are required. 
This research must include children and adolescents in both developing and developed 
countries and address long-term health outcomes.
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Abbreviations: AUC, area under the curve; CF, cystic fibrosis; cHRCT, chest high-resolution computed tomography; CI, 
confidence interval; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; CSLD, chronic suppurative lung 
disease; FEV1%, forced expiratory volume in one-second percentage; NPV, negative predictive value; NSAIDs, non-steroidal 
anti-inflammatory drugs; OR, odds ratio; OTC, over-the-counter; PBB, protracted bacterial bronchitis; PPV, positive predictive 
value; QoL, quality of life; RCT, randomized controlled trial; rhDNase, recombinant human DNase; RR, relative risk; TSANZ, 
Thoracic Society of Australia and New Zealand; US, United States.
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iNTRODUCTiON
Chronic (>4  weeks duration) wet cough in children implies 
increased airway secretions and lower airway infection (1). It 
is associated with often unrecognized morbidity and impaired 
quality of life (QoL) scores (2, 3). Within Australia, the most 
common cause of chronic wet cough in children is protracted 
bacterial bronchitis (PBB), followed by bronchiectasis (4). These 
two entities are at the opposite ends of a spectrum of overlapping 
conditions characterized by chronic wet cough, airway neutro-
philia, and high bacterial densities in bronchoalveolar lavage 
(BAL) fluid cultures (5). They also share a common risk factor 
of impaired airway clearance facilitating microbial colonization 
of the lower airways (6), while their lower airway microbiota are 
dominated by strains of non-typeable Haemophilus influenzae 
(NTHi), Streptococcus pneumoniae, and Moraxella catarrhalis  
(1, 7–15).
Protracted bacterial bronchitis is defined as an illness with an 
isolated wet cough >4 weeks duration that resolves with a pro-
longed 2–4 weeks of appropriate oral antibiotic treatment, usually 
amoxicillin–clavulanate, and where other pointers suggestive of 
an alternative cause of cough are absent (16). It is a relatively 
newly defined diagnosis, but likely represents illnesses previously 
termed as chronic bronchitis, persistent endobronchial infection, 
or pre-bronchiectasis (16, 17).
By contrast, bronchiectasis has many underlying causes and 
is diagnosed when there is a chronic wet cough, which has a 
variable response to even prolonged courses of oral antibiotics, 
frequent respiratory exacerbations, and radiographic demonstra-
tion of irreversible dilatation of one or more bronchi (18). These 
children often have other accompanying respiratory symptoms 
and signs too, including growth failure, exertional dyspnea, digi-
tal clubbing, chest wall deformity, hyperinflation, and adventitial 
sounds on chest auscultation. The most common etiologies of 
bronchiectasis in children include post-infectious causes follow-
ing recurrent and/or severe lower respiratory infections in early 
life, cystic fibrosis (CF), primary ciliary dyskinesia, immunode-
ficiency, retained foreign body, and chronic aspiration (12, 18).
Between the diagnostic spectrum of PBB and bronchiectasis 
are children with chronic suppurative lung disease (CSLD) who 
have the clinical symptoms and signs suggestive of bronchiec-
tasis but lack the chest high-resolution computed tomography 
(cHRCT) scan evidence to support a diagnosis of bronchiectasis, 
such as an increased broncho-arterial ratio and absence of bron-
chial tapering while progressing toward the lung periphery (18, 
19). Some of those categorized as having CSLD live in remote 
Indigenous communities in Australia and Alaska where undergo-
ing cHRCT scans is difficult logistically and may be delayed until 
late in adolescence. Consequently, some of the younger children 
with CSLD may have undiagnosed bronchiectasis. In light of this 
and as management is the same for both diagnostic entities (19), 
this review focuses upon preventing respiratory exacerbations in 
children with either CSLD or bronchiectasis.
While published data are currently limited, recurrent episodes 
of PBB can also occur. In a study of 106 children with PBB 
followed for 2 years (20), 43.5% had >3 episodes per year and 
bronchiectasis was diagnosed subsequently in 8.1% of study 
participants (20). H. influenzae infection in the lower airways 
and recurrent episodes of PBB were independently associated 
with a future diagnosis of bronchiectasis [odds ratio (OR) 7.60, 
95% confidence interval (CI) 1.53, 37.79 and OR 11.48, 95% 
CI 2.33, 56.50, respectively] (20). Nevertheless, children with 
recurrent PBB are not included in this review as the point where 
they progress to CSLD or bronchiectasis is yet to be determined, 
especially if they respond promptly to antibiotics and do not have 
additional symptoms or signs of respiratory disease. While CF 
is an important cause of chronic wet cough and bronchiectasis, 
children with CF are also excluded here given differences in the 
type of disease and concerns that the findings of studies in this 
patient population should not be extrapolated to those with 
bronchiectasis unrelated to CF (21).
ACUTe PULMONARY eXACeRBATiONS
Acute pulmonary exacerbations are associated with disease 
severity (7), and although there are no direct data for CSLD or 
bronchiectasis in children, exacerbations are likely to contribute 
to a decline in lung function. Determinants of accelerated lung 
function decline in adults with bronchiectasis are frequency of 
hospitalized exacerbations, increased systemic inflammatory 
markers, and infection with Pseudomonas aeruginosa (22). 
Among other factors, increased mortality risk is associated 
with degree of lung function impairment (23). In children, 
studies from Australia and the United Kingdom reported that 
children with normal lung function at the time bronchiectasis 
was diagnosed maintained normal lung function 5  years later 
(24–26). Those children with poor lung function at diagnosis, 
although substantially improved, were still likely to have poor 
lung function 5 years afterward with the only significant predic-
tor of pulmonary decline being the frequency of hospitalized 
exacerbations (25). With each hospitalized exacerbation, the 
forced expiratory volume in 1-s percentage (FEV1%) predicted 
decreased by 1.95% adjusted for time (25). Thus, interventions 
that minimize exacerbation frequencies are likely to be important 
in the overall management of bronchiectasis (19). In addition, 
preventing exacerbations will potentially reduce the associated 
economic and social costs. In the United States, between 1993 and 
2006, the median cost for adult inpatient care was US$7,827 (27). 
Hospitalization rates increased significantly over the study time 
period with an annual percentage increase of 2.4% for males and 
3.0% for females (27). At a New Zealand Hospital in 2004, half of 
the service’s pediatric bronchiectasis patients required at least one 
hospital admission per year (range 1–10) for exacerbations (28). 
The mean length of stay was 7 days (range 1–25). Eight percent 
of these children had regular three to four monthly admissions 
for 14 days to maintain respiratory status at a mean cost in 2004 
of US$5,492 (not including theater time or costs for inserting 
peripherally inserted central catheter vascular lines) for each 
hospitalization (28).
DeFiNiTiON
As with the paucity of data on CSLD and bronchiectasis in children 
in general (29), there is a dearth of literature defining an acute 
BOX 1 | Proposed criteria for defining a pulmonary exacerbation in 
children with bronchiectasis (37).
(I) Major criteria
o Significant frequency of cough (median cough score ≥2) over 72 h.
o Wet cough for 72 h.
(II) Minor criteria
o Sputum color ≥3 on BronkoTest™.
o Parent/child perceived breathlessness.
o Chest pain.
o Auscultatory crackles.
o Wheeze.
o Hypoxia (oxygen saturation ≤93% by pulse oximetry).
(III) Laboratory criteria
o CRP >3 mg/L on high sensitive testing.
o Serum interleukin-6 >2 ng/L.
o Serum amyloid-A >5 mg/L.
o Raised peripheral blood neutrophil % (age appropriate).
The three combinations considered the best to define an exacerbation:
• (Option-A) One major PLUS any one laboratory criteria positive [sensitivity 
63%, specificity 94%, AUC 0.784, p <  0.001; positive predictive value 
(PPV) 91%, negative predictive value (NPV) 71.6%], OR
• (Option-B) Two major criteria positive (sensitivity 92.6%, specificity 75.3%, 
AUC 0.84, p < 0.001; PPV 79%, NPV 91%), OR
• (Option-C) One major PLUS any two minor criteria positive (sensitivity 95%, 
specificity 75%, AUC 0.84, p < 0.001; PPV 78.5%, NPV 93.75%).
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exacerbation. In adults, acute exacerbations of chronic obstruc-
tive pulmonary disease (COPD) are characterized by worsening 
dyspnea and increasing sputum volume and/or purulence (30). In 
adult bronchiectasis, exacerbations have similar features to that 
of COPD with increased cough frequency and sputum volume 
or purulence and are often associated with culturing respiratory 
bacterial pathogens in sputum (31). In research settings, par-
ticularly studies with exacerbations as the primary outcome, 
the definition may also include the need for hospitalization and 
intravenous antibiotics (32).
Clinical trials in children are currently using (33–36) similar 
definitions to that used in adults, including variations in symp-
toms of increased cough, dyspnea, increased sputum volume or 
color intensity, new chest examination or radiographic findings, 
deterioration in FEV1% predicted >10%, or hemoptysis. Not all 
definitions have, however, included the need for hospitalization 
or intravenous antibiotics.
In a study of 30 children with 115 exacerbations of bronchiec-
tasis (25), increased cough frequency (88%) and change in cough 
character (67%) were the most frequent symptoms reported. 
Fever (28%), increased sputum volume (42%) and purulence 
(35%), and deteriorating chest auscultatory findings (58%) were 
also common, while changes in spirometry values compared to 
the stable state were not (25). Further work was undertaken from 
this cohort’s data (81 exacerbations included) (37) to develop a 
standardized definition of an exacerbation in children with bron-
chiectasis. Wet cough and cough severity (score ≥2) over 72 h 
were the best predictors of an exacerbation [receiver operating 
characteristic area under the curve of 0.85 (95% CI 0.79, 0.92) 
and 0.84 (95% CI 0.77, 0.91), respectively] (37). Sputum color, 
dyspnea, hemoptysis, chest signs, and chest pain were considered 
minor criteria and the addition of serum C-reactive protein 
(CRP), amyloid-A, and interleukin-6 improved the specificity 
and positive predictive value of the definition (37). The authors 
subsequently classified symptoms and laboratory measures into 
three sets of criteria (major, minor, and laboratory—Box  1) 
and then devised three options that could be used to define 
an exacerbation in bronchiectasis (Box  1). A limitation of the 
study is that there was a lack of an objective gold standard for 
diagnosing an exacerbation in bronchiectasis and hence the cri-
teria were assessed against a pediatric pulmonologist’s definition 
that included change in symptoms and the need for additional 
treatment beyond the stable state. Further studies validating the 
definition in larger cohorts are now awaited.
eTiOLOGY
The exact cause of exacerbations in young children with CSLD or 
bronchiectasis is not well understood, and it is unclear whether 
these are new infections, a resurgence of chronic infection, or a 
combination of both (31, 38). Part of the problem is that despite 
their regular use in clinical practice, upper airway secretions col-
lected by throat or cough swabs do not reliably predict organisms 
within the lower airways (9), especially as the potential pathogens 
of interest (NTHi, S. pneumoniae, and M. catarrhalis) are also 
found commonly in the upper airway spaces of healthy children 
(39). Repeated bronchoscopies with multi-lobar BAL to collect 
lower airway specimens before, during, and following acute 
exacerbations in children too young to reliably expectorate spu-
tum would be ideal, but impractical given their invasive nature, 
including the need for repeated sedation or general anesthesia. 
Hence the data required to confidently assign causality in research 
and patient care are limited.
Haemophilus influenzae, S. pneumoniae, and M. catarrhalis 
are frequently isolated at high densities (≥104 colony-forming 
units/mL) from BAL specimens collected from children and 
adults during an acute exacerbation, but mixed infections are 
also common (9, 13), and few studies have searched systemati-
cally for viruses. P. aeruginosa and non-tuberculous mycobac-
teria are uncommon in children with bronchiectasis and, when 
present, raises the possibility of undiagnosed CF while also being 
associated with more severe underlying bronchiectasis and co-
morbidities (13). A small study of 69 children with bronchiectasis 
that included 900 child-months of follow-up (40) identified at 
least one respiratory virus in nasopharyngeal aspirates in 48% of 
exacerbations, most commonly human rhinovirus (54% of virus-
positive events). Children with virus-positive exacerbations were 
more likely to require hospitalization (59 vs 32.5%; p =  0.02), 
have fever (OR 3.1, 95% CI 1.2, 11.1), hypoxia (OR 25.5, 95% CI 
2.0, 322.6), chest signs (OR 3.3, 95% CI 1.1, 10.2), and raised CRP 
(OR 4.7, 95% CI 1.7, 13.1), when compared with virus-negative 
exacerbations (40).
In a cross-sectional study of 245 children diagnosed with PBB 
or mild bronchiectasis undergoing bronchoscopy and BAL for 
clinical indication (median age 30 months) (41), a standard res-
piratory panel for viruses using polymerase chain reaction assays 
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was performed on all specimens. Human adenovirus (HAdV) was 
the most common virus detected, being identified in 40 children; 
influenza virus was detected in 3 children, parainfluenza virus in 
12, respiratory syncytial virus in 11, and human metapneumovi-
rus in 5 children (41). HAdV detection was more common in the 
young age groups (p = 0.001) and was positively associated with 
each of the three major bacterial pathogens (41). However, this 
association disappeared after adjustment for age and, given both 
the cross-sectional nature of the study with a lack of controls, a 
causal association between detecting these viruses and clinical 
illness at the time of bronchoscopy cannot be determined.
Similarly, there are very few studies examining the risk fac-
tors for exacerbations of CSLD or bronchiectasis. A study of 
93 Indigenous children from Alaska and Australia with CSLD 
or bronchiectasis (42) reported 74% of children experienced 
>2 exacerbations over a 3-year period. In this study, the factors 
associated with recurrent episodes were young age (<3  years), 
hospitalization for an acute exacerbation in the first-year of life, 
and pneumonia or hospitalization for an acute exacerbation in 
the year preceding enrollment (42). Exacerbations are also more 
frequent in severe bronchiectasis, and one study of 111 children 
reported that intensive medical intervention reduced the annual 
exacerbation rate by 56%; however, children still experienced a 
mean of 2.9 episodes per year (43).
PReveNTiON
Preventing exacerbations and reducing severity, are important 
goals in managing children with CSLD or bronchiectasis in order 
to maintain lung health and enhance their QoL (19). The corner-
stone of CSLD management is a combination of airway clearance 
techniques and antibiotic therapy, with or without other therapies 
such as anti-inflammatory agents and bronchodilators (31, 38, 
44). However, moderate or high-quality studies in children for 
either CSLD or bronchiectasis are limited (45), including those 
addressing broader approaches such as vaccines, health promo-
tion, and chronic disease management strategies.
Pharmacological Agents
Antibiotics
A Cochrane review of antibiotic efficacy for preventing recur-
rent lower respiratory tract infections in high-risk children aged 
<12 years (46) identified a lack of evidence supporting prophy-
lactic antibiotics and emphasized the need for high-quality trials 
to be conducted. That review included three studies involving 
children infected with human immunodeficiency virus, four with 
CF, and one each with children with sickle cell disease, cancer, 
and low birth weight neonates in a pediatric intensive care unit 
with underlying respiratory disorders (46). The only studies that 
addressed acute respiratory exacerbations were three of the CF 
studies; one (82 children) used ciprofloxacin in conjunction with 
colistin (polymyxin E) (47) and two (total of 312 children) used 
azithromycin (48, 49). The review excluded five studies [four in 
children with CF (50–53) and one involving children with either 
CSLD or bronchiectasis (54)] on the grounds that the children 
were already infected (51–54) or where infection could not be 
discounted (50). Given the underlying nature of these endobron-
chial disorders, where infection has a central pathogenic role, the 
justification for excluding the five studies is unconvincing, while 
the basis for being currently infected by unidentified organisms 
is also unclear.
In the Australian study excluded from the review (54), 89 
children with either CSLD or bronchiectasis were randomized 
to receive either azithromycin (30  mg/kg once-a-week) or pla-
cebo for up to 24 months. Children receiving azithromycin had 
significantly lower exacerbation rates (incidence rate ratio 0.50; 
95% CI 0.35, 0.71) than the control group (54). However, children 
in the azithromycin group also developed significantly higher 
carriage of azithromycin-resistant bacteria (19 of 41, 46%) than 
those receiving placebo (4 of 37, 11%; p = 0.002) (54). Acquiring 
macrolide-resistant organisms was more prevalent in those who 
were poorly adherent (76%) than those complying with their 
therapy (52%; OR 2.94, 95% CI 1.23, 7.14) and post-intervention 
Staphylococcus aureus strains remained resistant to macrolides 
(55). These findings support a role for directly observed therapy 
in individuals and communities where adherence may be subop-
timal, which will then help to ensure the benefits of long-term 
antibiotics, while minimizing potential harm from acquiring 
antibiotic-resistant organisms. A dose–response relationship 
between azithromycin use and an increase in macrolide-resistant 
strains of S. pneumoniae and S. aureus in the nasopharynx was 
also observed in a prospective study of 79 remote Australian 
children with CSLD or bronchiectasis conducted between 2004 
and 2008 (56). These findings are consistent with those of the 
2015 Cochrane review (57), which reported a threefold increase 
in antibiotic-resistant bacteria.
The 2015 Cochrane review of the efficacy of long-term 
antibiotics (≥4  weeks duration) in children and adults with 
bronchiectasis (57), identified only three studies (33, 58, 59) that 
included children (total 148 participants), and one did not report 
exacerbations (58). Of the remaining two, one used oral azithro-
mycin and is described above (54), and the second used either 
oral roxithromycin or placebo in 25 children for 12 weeks (59). 
This latter study failed to demonstrate a statistically significant 
difference in exacerbation rates, likely a result of the small sample 
size and short duration of follow-up, although the point estimate 
of effect provided a weak signal toward a reduction (OR 0.16, 95% 
CI 0.01, 3.60) (59). The study did, however, report significantly 
lower sputum purulence scores in the antibiotic group compared 
with those receiving placebo (1.39 ± 0.6 vs 2.17 ± 0.72; p < 0.01) 
(59). With respect to short-term antibiotics (<4 weeks duration), 
a further Cochrane review (60) identified no studies in children 
and, therefore, concluded there was no evidence to support this 
approach for reducing the severity and frequency of exacerba-
tions in children with bronchiectasis.
Expectorants, Mucolytics, and Mucokinetics
Retained mucus in the lower airways promotes bacterial growth, 
persistent airway inflammation, and bronchial wall injury (61). 
Hence reducing mucus retention is an important aspect of airway 
clearance techniques. Mucoactive agents include expectorants, 
mucolytics, and mucokinetic agents.
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Expectorants aim to increase the volume of airway water or 
secretion in order to increase the effectiveness of cough (62) and 
include both over-the-counter (OTC) cough medications and 
inhaled hyperosmolar saline and mannitol. There is no good 
evidence for the use of OTC cough medications and expectorants 
in children (63), and concerns about adverse events, including 
some reports of infant deaths (64), led to several countries recom-
mending OTC cough medications should not be given to young 
children. Inhaled hyperosmolar agents, including hyperosmolar 
saline and mannitol, potentially alter the physical properties of 
mucus by increasing water in the airway lumen and disrupting 
mucin networks (65). While there is evidence to support the 
role of hyperosmolar agents in children with CF (62), there are 
insufficient data to support their use in children with CSLD or 
bronchiectasis (45).
Mucolytics make mucus less viscous so that it can be more eas-
ily expectorated, and they are available in both oral and inhaled 
forms. This group of drugs includes N-acetylcysteine, ambroxol 
(3), sobrerol, carbocysteine, sobrerol, letosteine, cithiolone, 
iodinated glycerol, N-isobutyrylcysteine, myrtol and erdosteine, 
and recombinant human DNase (RhDNase) (62). The exact 
mechanism of action of most mucolytics is unclear, except for 
RhDNase that targets neutrophils at the site of infection in the 
lungs (66, 67). There have been no pediatric trials of mucolytics in 
children with CSLD or bronchiectasis (66). Moreover, RhDNase 
is not recommended in either children or adults with bronchiec-
tasis given a study in adults reporting its negative effects on lung 
function and exacerbation rates (68).
Mucokinetics increase the effectiveness of cough, either by 
increasing expiratory cough airflow or by removing secretions 
from the airway walls; aerosol surfactant is one of this class of 
medications (62). However, as with the other pharmacologic 
airway clearance therapies described above, there is no high-
level evidence to support their use in children with CSLD or 
 bronchiectasis (69).
Bronchodilators
Bronchiectasis may be associated with an obstructive ventilatory 
defect, which may worsen during an exacerbation (70). Although 
patients with bronchiectasis may also have asthma (71) and the 
presence of bronchiectasis may worsen asthma exacerbations 
(72), small adult studies suggest the airflow limitation is not 
readily reversible (73). There are, however, scarce data on the 
prevalence of asthma in children with CSLD or bronchiectasis, 
although there are suggestions that children with either CSLD or 
bronchiectasis have been misdiagnosed with asthma previously 
(19). There are no trials of bronchodilators in children with 
CSLD or bronchiectasis in the absence of a confirmed diagnosis 
of asthma, and their use in this group of children is not recom-
mended currently (74).
Corticosteroids
Airway inflammation is a key characteristic of both CSLD and 
bronchiectasis where the resultant symptoms can be similar or 
falsely attributed to asthma (75). While the data are limited, 
the presence of asthma-like symptoms in the presence of 
bronchiectasis has been associated with accelerated lung func-
tion decline (76–78). Inhaled corticosteroids are commonly used 
to control asthma symptoms, including preventing exacerba-
tions. This class of drugs demonstrates broad anti-inflammatory 
actions, which can occur either rapidly or over a period of hours 
or days (79). Side effects are, however, not uncommon, and there 
are data to suggest children with persistent asthma receiving 
daily high-dose inhaled corticosteroids have an increased risk of 
linear growth faltering over a 12-month treatment period (80). 
Furthermore, for this strategy to be effective treatment, adher-
ence is especially important (81) and, while data are limited 
in children with CSLD or bronchiectasis, non-adherence to 
inhaled corticosteroids regimens in adults with bronchiectasis 
has been documented (81, 82), and is known to be problematic 
in children with asthma, particularly adolescents. A Cochrane 
review of inhaled corticosteroids in children and adults with 
bronchiectasis identified no pediatric studies, and hence there is 
no available evidence to support their use (75). However, a small 
study of inhaled corticosteroid withdrawal over a 12-week period 
in 27 children with bronchiectasis (83) reported a significant 
increase in bronchial hyper-reactivity after ceasing the drug (37.0 
vs 46.8%, p =  0.016) and a decrease in neutrophilic apoptosis 
in induced sputum (42.8 vs 20.2%, p = 0.03), but no change in 
sputum inflammatory markers or in the number of infectious 
exacerbations (83). Larger studies are required to confirm these 
findings and to determine whether they are of any clinical 
significance. By contrast, the role of systemic corticosteroids 
in children or adults with CSLD or bronchiectasis has not been 
examined (84, 85).
Non-Steroidal Anti-inflammatory Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) are a class of 
medications that act as non-selective inhibitors of the enzyme 
cyclo-oxygenase and induce analgesic, antipyretic, and anti-
inflammatory effects. Both oral and inhaled NSAIDs are avail-
able. A recently updated Cochrane review of inhaled NSAIDS 
in children and adults with bronchiectasis identified no relevant 
trials of NSAID efficacy in children and concluded there was no 
evidence to either support or refute their use in bronchiectasis 
(86). Another review of the efficacy of oral NSAIDs published in 
2007 identified no trials in children or adults and could, therefore, 
make no recommendations regarding their use (87).
Vaccines
With respect to pathogens associated with respiratory illnesses, 
pediatric vaccines currently exist for influenza, S. pneumoniae 
(23 valent polysaccharide vaccine and 7, 10, and 13 valent pneu-
mococcal conjugate vaccines), Bordetella pertussis, H. influenzae 
type b, measles, and varicella. The 10-valent pneumococcal vac-
cine uses Protein D, an outer membrane protein derivative from 
NTHi strains, as the conjugate. There is currently no evidence 
for any of these vaccines in preventing acute exacerbations 
of either CSLD or bronchiectasis in children (88), primarily 
because the trials have not been done. A randomized controlled 
trial (RCT) of the 10-valent pneumococcal Protein D conjugate 
vaccine in children with CSLD or bronchiectasis using acute 
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exacerbations as the primary endpoint has concluded recently 
in Australia (36), although the results were not yet published at 
the time of this review. The need for a safe and effective vaccine 
targeting NTHi for children is being recognized increasingly 
as a  priority preventive and therapeutic intervention (89–91). 
Despite the lack of evidence for preventing exacerbations, 
children with chronic lung diseases are at high risk for severe 
infections from most of these organisms (92–94), and disease 
management should include ensuring children receive on-time 
and age-appropriate immunizations in all countries where these 
vaccines are recommended through national immunization 
programs.
Non-Pharmacological Airway Clearance 
Techniques
Non-pharmacological airway clearance techniques are strategies 
that aim to clear the airway of secretions, improve gas exchange, 
and hence reduce the risk of infection in the lower airways (95). 
The core components involve postural drainage, percussion, 
vibration of the chest wall, and coughing (96), and specific 
techniques include active cycle of breathing techniques, forced 
expiration techniques, autogenic drainage, postural drainage, 
oscillating positive expiratory pressure, high frequency chest wall 
oscillation, and exercise and/or pulmonary rehabilitation (96). 
While a Cochrane review found these techniques have clinically 
important effects on health-related QoL scores in adults (97), it 
identified only one study in children with bronchiectasis (98). 
This study involved only nine children with bronchiectasis and 
the intervention was oscillatory positive expiratory pressure 
administered three times a day with lung function measured 
after a 3-month period. The study did not include exacerbations 
as an outcome. Despite the lack of trials, non-pharmacological 
airway clearance techniques are recommended in managing 
children with CSLD or bronchiectasis (71, 74, 99) given the need 
to reduce mucus retention in the lower airways. The efficacy of 
these treatments with respect to preventing exacerbations is 
unknown.
Chronic Disease Management Plans
The complexity of managing patients with chronic diseases 
necessitates a multi-disciplinary approach that involves shared 
decision-making and includes the patient and their carers/family 
in developing treatment plans (100, 101). Personalized chronic 
disease management plans involve joint goal setting and agree-
ment on actions necessary to achieve those goals (102). A system-
atic review of 19 studies involving 10,856 adults with a range of 
chronic health conditions concluded that modest improvements 
can be made through personalized management plans in physical 
and psychological parameters, as well as in patient capacity to self-
manage their conditions (102). There appears to be no published 
studies of the efficacy of chronic disease management plans in 
preventing exacerbations of CSLD or bronchiectasis in children. 
A systematic review of action plans for adults with COPD that 
included limited self-management education identified improve-
ments in the recognition of, and initiation of treatment for, acute 
exacerbations, but there was no evidence for reduced health-care 
utilization or improved health-related QoL (103). A review of 
shared care of people with chronic diseases between primary 
and specialty health services concluded there was insufficient 
evidence for the benefits of that approach other than improved 
prescribing (104).
Health Promotion Strategies
Optimizing healthy growth and development is important for 
all children; however, additional efforts are required for children 
with CSLD or bronchiectasis given the links between respiratory 
infections and key factors, such as nutrition, exposure to envi-
ronmental toxicants (particularly tobacco smoke), and healthy 
weight.
Optimize Nutritional Status
Nutritional deficiencies in children may lead to poor lung 
function, increased susceptibility to infections, and a greater 
likelihood of acute illnesses in childhood and chronic illness 
in adulthood (105). Micronutrient deficiencies, particularly of 
vitamins A, C, and D, folic acid, and the trace elements, zinc 
and iron, have been linked to many childhood infectious dis-
eases, including respiratory infections (105). There is increasing 
interest in the role of vitamin D in respiratory diseases given its 
modulatory and regulatory role in inflammation and immunity 
(106). There are some data suggesting adults with chronic lung 
diseases are frequently deficient (107) and that deficiency is 
associated with disease severity (108). However, the studies 
supporting a role for vitamin D in protection against acute and 
chronic respiratory infections are associative and come from 
observational studies. A recent systematic review and meta-
analysis of seven RCT of vitamin D supplementation in 6,503 
children aged <18 years found no evidence to support their use 
for preventing or treating acute respiratory infections in healthy 
children (109). Interestingly, in this meta-analysis, vitamin D 
supplementation reduced the risk of asthma exacerbations by 
74% [relative risk (RR) 0.26, 95% CI 0.11, 0.59], although this 
result needs to be interpreted cautiously as it involved two small 
studies of 430 and 48 subjects, respectively, and where signifi-
cant heterogeneity was observed. Thus larger RCT are needed 
to determine whether vitamin D supplementation can reduce 
the risk of acute asthma exacerbations and if it should also be 
studied in children with other chronic lung diseases, including 
CSLD and bronchiectasis.
In addition, high intake of fructose-containing beverages such 
as soft drinks and fruit juice has been associated with increased 
prevalence of asthma in children (110, 111) and with chronic 
bronchitis in adults (112). Currently, there are no data on the role 
of micronutrient deficiencies, micronutrient supplementation, 
and high fructose intake in children with either CSLD or bron-
chiectasis. However, promoting a healthy diet is important for all 
children. A study of 141 Polish children with recurrent bronchitis 
found higher levels of body fat and muscle mass deficiency com-
pared to reference ranges for healthy children (113). Whether 
this result reflects cause or effect is unknown, but while there are 
no efficacy trials of weight reduction in preventing exacerbations 
of pediatric CSLD or bronchiectasis, there are some data, albeit 
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limited, to suggest an effect in adults with asthma (114). Given 
the global rise of high calorie diets and associated obesity, and the 
complex socioeconomic circumstances where that has occurred, 
reducing calorie intake in children requires a multi-sectorial, 
population-based approach that includes strong government 
policy (115).
Reduce Exposure to Tobacco Smoke
Active and passive exposure to tobacco smoke is well-known 
as important risk factors for respiratory diseases. Children of 
parents who smoke are at approximately twice the risk of being 
hospitalized for respiratory illnesses (116). Hence avoiding 
exposure is not only beneficial to lung health but reduces the 
risk of the multitude of other adverse health outcomes associated 
with smoking. While knowledge around the effects of a child’s 
passive exposure to tobacco smoke is improving in some settings 
(117), challenges remain in improving community and smoker 
perceptions of the risk to children, including among families of 
children with chronic lung diseases (117–119). Several strategies 
have been studied to reduce household tobacco smoke exposure 
in children, including motivational interviewing (with or without 
education) (120), maternal and child health nurse interventions 
(121), and family-centered interventions (122); however, the 
effectiveness of many strategies is modest at best (123).
Efforts are required to ensure children with CSLD or bron-
chiectasis do not take up smoking, particularly as they enter 
the vulnerable adolescent and young adult years (124). This 
must include efforts to prevent the use of e-cigarettes, which 
are becoming increasingly popular among adolescents despite 
emerging evidence to suggest adverse health effects (125). In a 
study of 2,086 North American adolescents of e-cigarette use 
and reported chronic cough, sputum production, or bronchitis 
symptoms in the previous 12 months (126), the risk of symptoms 
was almost twofold higher among past users (OR 1.85, 95% CI 
1.37, 2.49), compared to never users, and by 2.02-fold (95% CI 
1.42, 2.88) among current users. The risk also increased with 
frequency of current use (126).
Physical Activity
Promoting physical activity in children and adolescents should be 
standard practice for health-care providers given its well-known 
benefits to overall health and well-being. However, chronic 
illness can impact on activity levels in children, potentially 
affecting disease progression (127, 128). People with advanced 
lung disease experience static and dynamic hyperinflation due 
to airflow limitation, leading to reduced tidal volumes, increased 
dead space ventilation, and exertional dyspnea making exercise 
difficult (127). Physical activity provides higher health-related 
QoL scores (129) and greater aerobic capacity (130).
A study of an 8-week exercise training program in 55 
adults with bronchiectasis who were subsequently followed for 
12 months (131) reported fewer exacerbations in the interven-
tion group compared to controls (RR 0.69) (95% CI 0.49, 0.98) 
as well as fewer exacerbations that required antibiotics. There 
are no data on the patterns of physical activity in children with 
CSLD or bronchiectasis, nor are there data on the effective-
ness of physical activities in reducing exacerbations in these 
children.
CONCLUSiON
Chronic suppurative lung disease and bronchiectasis in children 
and adolescents are serious illnesses with significant adverse 
impacts on the child, their family, the health-care sector, and 
broader community. Despite this, there has been scant attention 
paid to the spectrum of disease, its management, and preven-
tion in comparison to CF and chronic lung diseases in adults. 
Exacerbations of CSLD and bronchiectasis in children are 
important predictors of lung function decline and are associated 
with significant morbidity. Preventing exacerbations should, 
therefore, be the cornerstone of long-term disease management. 
However, there are only limited data on preventing acute res-
piratory exacerbations in children with CSLD or bronchiectasis. 
Hence management is currently informed largely by clinical 
opinion and extrapolating data from adults and/or children with 
CF and asthma, Unfortunately, such an approach is not without 
risk, where treatments highly successful in CF patients such as 
inhaled rhDNase, tobramycin, aztreonam, and colistin have pro-
vided disappointing results in adults with bronchiectasis (132). 
A standardized, validated definition of an acute exacerbation in 
children with CSLD and bronchiectasis is needed urgently as 
an outcome measure in clinical trials and to help guide clinical 
practice. In a similar vein, studies to determine when recurrent 
episodes of PBB should be classified and managed as CSLD are 
also required. Substantially more, and larger studies, are needed to 
determine the efficacy and effectiveness of both pharmacological 
and non-pharmacological interventions to prevent exacerbations. 
These studies must also include health-related QoL assessments 
and cost-effectiveness of the interventions. Given the burden 
of disease is likely to be highest in low- and middle-income 
countries, measures to prevent exacerbations must be translated 
to low socioeconomic and disadvantaged community and health-
care settings that do not have access to the drugs and technology 
available in high-income nations.
For the clinician, the lack of robust well-designed, interven-
tion-based RCT to guide prevention of acute exacerbations of 
CSLD and bronchiectasis in children and adolescents means that 
guidelines are more consensus than evidence-based. We follow 
the Thoracic Society of Australia and New Zealand (TSANZ) 
guidelines (19, 74) where children and adolescents are seen three 
times monthly and where we recommend they practice regular 
airway clearance techniques in consultation with a pediatric 
respiratory physiotherapist, encourage physical activity, moni-
tor growth and optimize nutrition, counsel against active and 
passive tobacco smoke exposure, promote avoidance of other 
environmental inhaled toxicants, and ensure they receive their 
vaccinations according to the National Immunization Program, 
including the pneumococcal and annual seasonal influenza 
vaccines. At the same time, co-morbidities, such as underlying 
immunodeficiency or chronic aspiration, are often managed with 
the aid of other specialty services. Children and adolescents who 
are frequent exacerbators (≥3 exacerbations and/or ≥2 respira-
tory hospitalizations in the previous 12 months) are prescribed 
low-dose oral azithromycin for a trial period of 12–24 months 
according to the TSANZ guidelines. Selected patients are offered 
inhaled hypertonic saline as a mucoactive agent and/or an 
inhaled antibiotic, usually tobramycin, if exacerbations continue, 
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especially if they have a chronic P. aeruginosa infection of their 
lower airways. These agents are trialed separately and if tolerated 
are continued long term. Finally, bronchodilators and inhaled 
corticosteroids are administered only to those with an established 
diagnosis of asthma and are not used routinely for other patients 
with CSLD or bronchiectasis.
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